Triumvira Immunologics’ $100 Million Series A Financing Round

Latham & Watkins, Torys LLP and Goodwin represented Triumvira Immunologics in the transaction.Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics…

This content is for Standard 1 Year members only.
Login Join Now
Laura Testa

Author: Laura Testa

This content is for Standard 1 Year members only.
Login Join Now